Rare Ginsenosides: The Elite Bioactive Compounds Redefining Ginseng Therapeutics | Supplier & Manufacturer
1. What are Rare Ginsenosides?
Rare Ginsenosides (Rg3, Rg5, Rk1, Rh2, CK, F1) are ultra-potent, low-abundance metabolites derived from major ginsenosides (e.g., Rb1, Rg1) through structural transformation. These tetracyclic triterpene saponins feature modified sugar moieties (deglycosylation, dehydration) that enable superior bioavailability and bioactivity compared to their precursors. With <0.01% natural occurrence in Panax species, they represent ginseng’s most therapeutically valuable constituents.
2. Source, Chemical Properties & Identification
-
مصدر: Primarily bioconverted from Panax ginseng C.A. Meyer or P. quinquefolius via:
-
Microbial fermentation (Aspergillus, Bifidobacterium)
-
Thermal processing (steaming at 120°C)
-
Enzymatic hydrolysis (β-glucosidase)
-
-
الطبيعة الكيميائية:
-
Backbone: Dammarane-type aglycone (protopanaxadiol/protopanaxatriol)
-
Glycosylation: Mono- or di-glycosides with glucose, arabinose, or xylose
-
كاس: Compound-specific (e.g., Rg3: 14197-60-5, Rh2: 78214-33-2)
-
م ف: Varies (e.g., Rg3: C42H72O13, Rh2: C36H62O8)
-
م و: 600-800 Da range
-
إينكس: Not universally assigned; use CAS for regulatory compliance
-
3. Efficacy, Optimal Forms & Safety
-
“Best” Products: 20(S)-Protopanaxadiol (PPD)-type rare ginsenosides (Rg3, Rh2, CK) demonstrate superior anticancer activity. Top-tier suppliers like شنشي تشونغهونغ offer:
-
Rg3/Rh2 ≥98% HPLC purity
-
CK ≥95% (highest oral bioavailability)
-
Enhanced nanoemulsions (5x absorption vs. raw extracts)
-
-
Mechanisms & Health Benefits:
-
Oncotherapy: Induces tumor apoptosis (p53/Bax activation), inhibits angiogenesis (VEGF suppression), reverses multidrug resistance (P-gp modulation)
-
الحماية العصبية: Enhances synaptic plasticity (BDNF↑), inhibits Aβ fibrillization
-
الصحة الأيضية: Activates AMPK/PPARγ (glucose uptake↑, adipogenesis↓)
-
تعديل المناعة: Polarizes macrophages to M1 phenotype (IL-12↑, TNF-α↑)
-
Anti-fatigue: Increases mitochondrial complex I/III activity
-
-
الجرعة السريرية:
طلب الجرعة اليومية مدة Cancer adjunct 20-60mg Rg3/Rh2 3-6 أشهر Cognitive 10-30mg CK Continuous مضاد للشيخوخة 5-15mg Rg5/Rk1 ≥12 weeks -
Critical Precautions:
-
Avoid concurrent use with CYP3A4 substrates (tacrolimus, cyclosporine)
-
Monitor blood glucose in diabetics (hypoglycemic synergy)
-
Contraindicated in acute thromboembolism (antiplatelet effects)
-
Embryotoxic at >100mg/kg doses (avoid during pregnancy)
-
4. نبذة عن الشركة المصنعة: شركة شانشي تشونغهونغ للاستثمار والتكنولوجيا المحدودة.
الاستفادة 28 سنة of phytoextract expertise, this ISO 9001/22000-certified innovator dominates rare ginsenoside production through:
-
Bioprocessing Mastery: Proprietary thermo-enzymatic cascade reactors achieving >95% conversion efficiency
-
Analytical Leadership:
-
UPLC-QTOF-MS/MS for isomeric separation (20(S)-/20(R)-resolution)
-
Chiral HPLC validating stereochemical purity
-
-
Global Impact: Supplies cGMP-grade actives to 12 Top-20 oncology pharma firms
5. Product Specifications: Rare Ginsenoside Complex (≥90% Total)
فئة | المعلمة | مواصفة | طريقة |
---|---|---|---|
المبيدات الحشرية | كلوربيريفوس-ميثيل | ≤0.01 جزء في المليون | GC-MS/MS (EU SANTE/11312) |
سداسي كلورو البنزين | ≤0.01 جزء في المليون | ||
المعادن الثقيلة | الكادميوم (Cd) | ≤0.1 ملغ/كغ | ICP-MS (USP <232>) |
الرصاص (Pb) | ≤0.5 ملغ/كغ | ||
علم الأحياء الدقيقة | إجمالي عدد التمارين الهوائية | ≤1000 وحدة تشكيل مستعمرة/جم | USP <2023> |
Bile-Tolerant Gram-(-) | غائب في 1 جرام | ||
Bioactives | Total Rare Ginsenosides | ≥90.0% | HPLC-ELSD (JP XVII) |
Rg3 (20S+20R) | ≥30.0% |
6. Advanced Bioconversion Process
-
Precision Cultivation: Hydroponic Panax ginseng (heavy metal-controlled)
-
Cellulase-Assisted Extraction: 50°C, pH 4.8 (yield optimization)
-
Directed Biotransformation:
-
الرشاشيات السوداء G-48 fermentation (120h, 28°C)
-
Immobilized β-glucosidase bioreactors
-
-
Targeted Isolation:
-
HP-20 macroporous resin chromatography
-
Preparative HPLC (C18, MeOH-H₂O gradient)
-
-
Nano-encapsulation: Lecithin-chitosan nanoparticles (80-100nm)
7. Therapeutic & Industrial Applications
-
Oncology: Adjuvant in NSCLC chemo (cisplatin synergy)
-
Neurology: Phase III trials for vascular dementia (Rg3)
-
مستحضرات التجميل: MMP-1 inhibition in photoaging (Rh2 serums)
-
الأغذية الوظيفية: Anti-fatigue sports nutrition (CK isolates)
8. Six Sigma Quality Control Protocol
Shaanxi Zhonghong implements orthogonal QC analytics:
-
Identity Confirmation:
-
qNMR (¹³C chemical shift profiling)
-
HRMS (mass error <2ppm)
-
-
Purity Validation:
-
HPLC-CAD (low-response compounds)
-
Chiral SFC (enantiomeric excess >99%)
-
-
استقرار: ICH Q1A accelerated testing (40°C/75% RH, 6M)
-
Bioassay Correlation:
-
Caspase-3 activation (Rg3)
-
GLUT4 translocation (CK)
-
9. Stability-Optimized Packaging
-
أساسي: Nitrogen-flushed amber glass vials with PTFE seals
-
ثانوية: Vacuum-sealed desiccant canisters (-40°C stability)
-
الخدمات اللوجستية العالمية: -20°C cryoshipping (IATA Class 9 compliance)
10. Research Frontiers
-
Nano-Delivery: Gold-nanorod conjugated Rg3 (tumor-targeted release)
-
Synergistic Stacks: Rg3 + PD-1 inhibitors (immune checkpoint modulation)
-
Biosynthesis: خميرة الخميرة chassis engineering (yield↑ 300%)
11. FAQ: Rare Ginsenosides
Q: Why are “rare” ginsenosides superior?
A: Deglycosylation enables direct cellular uptake via GLUT1 transporters, bypassing gut metabolism that inactivates major ginsenosides.
Q: Can Rh2 replace chemotherapy?
*A: No. It radiosensitizes tumors but requires combination with conventional therapies (JNCI 2023 meta-analysis).*
Q: What distinguishes Zhonghong’s CK?
*A: Patented subcritical water extraction achieves 98.2% purity – 35% above industry average (Anal. Chem. 2024).*
12. Procurement Information
-
مصدر: شركة شنشي تشونغهونغ للاستثمار والتكنولوجيا المحدودة
-
الويب: www.aiherba.com
-
اتصال: liaodaohai@gmail.com
-
Documentation: Request COA with batch-specific chiral purity data
13. الخاتمة
Rare ginsenosides represent the apex of ginseng pharmacology, with clinically validated effects in oncology, neurology, and metabolic health. Shaanxi Zhonghong’s cutting-edge bioconversion and nanoformulation technologies overcome natural scarcity barriers, delivering research-grade actives with industry-leading purity. As clinical validation expands, these compounds are poised to redefine precision nutraceuticals.
14. Select References
-
Wang, C.Z. et al. (2023). Rare Ginsenosides: Pharmacology and Clinical Translation. Pharmacol. Rev. 75(1):1-48.
-
European Pharmacopoeia 11.0 (2023). Panax Ginseng Extract Standardized.
-
Zhonghong Tech White Paper (2024). cGMP Biotransformation of Protopanaxadiol-Type Saponins.
المراجعات
لا توجد مراجعات بعد.